3626 results for «394»
3626 results
Treatment of paravalvular leak
21 Nov 2023 – From PCR London Valves 2023
Explore innovative approaches in paravalvular leak management with this selection of cases: discover the unique strategy of employing three plugs to close a challenging mitral paravalvular leak, navigate the challenges of tackling device migration and retrieval in the closure of a sizable aortic paravalvular leak, gain...
Mitral valve interventions in challenging clinical situations
21 Nov 2023 – From PCR London Valves 2023
Discover innovative approaches to mitral valve interventions in challenging clinical situations: navigate the challenges of critical stenosis in a bioprosthetic mitral valve, learn more about the use of iVAC-2L in transcatheter edge-to-edge repair for a mitral valve lacking leaflet coaptation, explore mitral transcutaneous edge-to-edge repair guided by transthoracic...
Second time TAVI (TAV-in-TAV) - Not as simple as it looks
19 Nov 2023 – From PCR London Valves 2023
Although it is still rare, TAV-in-TAV is likely to become more frequent, as TAVI is increasingly implanted in younger patients. Harmonizing data in this area will therefore help to improve outcomes, the quality of which depends on site experience, bearing in mind that for the time...
Controlled ring expansion during aortic valve-in-valve: a proof-of-concept CT-scan analysis
24 Jun 2024
Analyze this EIJ image to see how surgical aortic bioprostheses with expandable ring technology can significantly enhance future ViV procedures.
Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial
20 Sep 2022
Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.
It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...
Author
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!
17 Oct 2020
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.
Author
